Journal of Oral and Maxillofacial Surgery
Volume 65, Issue 3 , Pages 415-423 , March 2007

Nature and Frequency of Bisphosphonate-Associated Osteonecrosis of the Jaws in Australia

  • Tony Mavrokokki, BDS

      Affiliations

    • Staff Dentist, Oral and Maxillofacial Surgery Unit, Adelaide Dental Hospital and University of Adelaide, Adelaide, South Australia.
    • Professor Goss has acted as a consultant to Novartis (International and Australia) and to Merck (International and Australia). Dr A. Mavrokokki has acted as a consultant to Novartis (Australia) and Dr A. Cheng to Merck (Australia).
    • ,
  • Andrew Cheng, BDS

      Affiliations

    • Registrar, Oral and Maxillofacial Surgery Unit, Royal Adelaide Hospital, Adelaide Dental Hospital and University of Adelaide, Adelaide, South Australia.
    • Professor Goss has acted as a consultant to Novartis (International and Australia) and to Merck (International and Australia). Dr A. Mavrokokki has acted as a consultant to Novartis (Australia) and Dr A. Cheng to Merck (Australia).
    • ,
  • Brien Stein, MBBS, FRACP

      Affiliations

    • Medical Oncologist, Ashford Cancer Center, Ashford, and University of Adelaide, Adelaide, South Australia.
    • ,
  • Alastair Goss, DDSC, FRACDS(OMS), FICD

      Affiliations

    • Professor and Director, Oral and Maxillofacial Surgery Unit, Royal Adelaide Hospital, Adelaide Dental Hospital, Adelaide, and Professor of Oral and Maxillofacial Surgery, School of Dentistry, University of Adelaide, Adelaide, South Australia.
    • Professor Goss has acted as a consultant to Novartis (International and Australia) and to Merck (International and Australia). Dr A. Mavrokokki has acted as a consultant to Novartis (Australia) and Dr A. Cheng to Merck (Australia).
    • Corresponding Author InformationAddress correspondence and reprint requests to Dr Goss: Oral and Maxillofacial Surgery Unit, The University of Adelaide, Adelaide, Australia, 5005

References 

  1. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg. 2003;61:1104
  2. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg. 2003;61:1115
  3. Migliorati CA. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol. 2003;21:4253
  4. Pogrel MA. Bisphosphonates and bone necrosis. J Oral Maxillofac Surg. 2004;62:391
  5. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg. 2004;62:527
  6. Lugassy G, Shaham R, Nemets A, et al. Severe osteomyelitis of the jaw in long-term survivors of multiple myeloma: A new clinical entity. Am J Med. 2004;117:440
  7. Carter G, Goss AN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: A possible association. Med J Aust. 2005;182:413
  8. Purcell PM, Boyd AW. ADRAC report: Bisphosphonates and osteonecrosis of the jaws. Med J Aust. 2005;182:417
  9. Bagan JV, Murillo J, Jimenez Y, et al. Avascular jaw necrosis in association with cancer chemotherapy: Series of 10 cases. J Oral Path Med. 2005;34:120
  10. Durie BGM, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005;353:99
  11. Schirmer I, Peters H, Reichart PA, et al. [Bisphosphonates and osteonecrosis of the jaw] Mund Kiefer Gesichtschir. 2005;9:239
  12. Maerevoet M, Martin C, Duck L. Osteonecrosis of the jaw and bisphosphonates (Letter to the editor). N Engl J Med. 2005;353:100
  13. Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bis-phossy jaw): Is this phossy jaw of the 21st century?. J Oral Maxillofac Surg. 2005;63:682
  14. Cheng A, Mavrokokki A, Carter G, et al. The dental implications of bisphosphonates and bone disease. Aust Dent J. 2005;50(suppl 2):S4
  15. Marx RE, Sawatari Y, Fortin M, et al. Bisphosphonate induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention and treatment. J Oral Maxillofac Surg. 2005;63:1567
  16. Fleisch H. Bisphosphonates: Mechanisms of action. Endocr Rev. 1998;19:80
  17. Sparidans RW, Twiss IM, Talbot S. Bisphosphonates in bone disease. Pharm World Sci. 1998;20:206
  18. Russell RGG, Rogers MJ. Bisphosphonates: From the laboratory to the clinic and back again. Bone. 1999;25:97
  19. Russell RGG, Croucher PI, Rogers MJ. Bisphosphonates: Pharmacology, mechanisms of action and clinical uses. Osteoporos Int. 1999;9(suppl 2):S66
  20. Fleisch H. Bisphosphonates in osteoporosis. Eur Spine J. 2003;12(suppl 2):S142
  21. Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev. 2002;(2):CD002068
  22. Ruggiero S, Gralow J, Marx R, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract. 2006;2:7
  23. Damato K, Gralow J, Hoff A, et al: Expert panel recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaws. (Novartis internal document). Available at: http://www.ada.org/prof/resources/topics/topics_osteonecrosis_whitepaper.pdf. Accessed May 2006
  24. Migliorati CA, Casiglia J, Epstein J, et al. Managing the care of patients with bisphosphonate-associated osteonecrosis. J Am Dent Assoc. 2005;136:1658
  25. Tarassoff P, Csermak K. Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg. 2003;61:1238
  26. Bamias A, Kastridis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol. 2005;23:8580
  27. Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol. 2006;26:945
  28. Legal. Ennis and Ennis PA: Fosamax class action. http://www.fosamax-lawyer.com/
  29. Carter GD, Goss AN. Letter to the editor (Bisphosphonates and avascular necrosis of the jaws). Aust Dent J. 2003;48:268
  30. Medicare Australia. http://www.medicareaustralia.gov.au
  31. Carter KD, Stewart JF. National Dental Telephone Interview Survey (2002 Adelaide). AUIHW, Statistics and Research Unit; 2003;
  32. Vudiniabola S, Pirone C, Williamson J, et al. Hyperbaric oxygen in the therapeutic management of osteoradionecrosis of the facial bones. Int J Oral Maxillofac Surg. 2000;29:435
  33. Saad F, Gleason DM, Murray R, et al. Zoledronic Acid Prostate Cancer Study Group (Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer). J Natl Cancer Inst. 2004;96:879
  34. Hortobagyi GN, Theriault RL, Lipton A, et al. Protocol 19 Aredia Breast Cancer Study Group Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol. 1998;16:2038
  35. Brennan DS, Spencer AJ, Singh KA, et al. Practice patterns of oral and maxillofacial surgeons in Australia: 1990 and 2000. Int J Oral Maxillofac Surg. 2004;33:598
  36. Swan N: Manuscript of recording on ‘Drug linked to death of jawbone’ The Health Report, ABC Radio National, March 27, 2006
  37. South Australian Government Legislation, Civil Liberty Act. Section 41, 1936
  38. Whittaker RV: High Court of Australia, 175 CLR 479, 1992
  39. Sambrook P, Olver I, Goss AN. Bisphosphonates and osteonecrosis of the jaw: Position statement on behalf of the Australian and New Zealand Bone and Mineral Society, Osteoporosis Australia, Medical Oncology Group of Australia and the Australian Dental Association. Aust Fam Physician. 2006;35:801

PII: S0278-2391(06)01963-X

doi: 10.1016/j.joms.2006.10.061

Journal of Oral and Maxillofacial Surgery
Volume 65, Issue 3 , Pages 415-423 , March 2007

Article Tools

* Image Usage & Resolution